EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population

Massimo Breccia iD, Antonella Russo Rossi, Valentina Giai, Bruno Martino, Carmen Fava, Mario Annunziata, Elisabetta Abruzzese, Gianni Binotto, Claudia Baratè, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco und 34 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Massimo Breccia und 45 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Pyrazoles, Protein Kinase Inhibitors, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Farma Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) patients who have experienced failure and/or intolerance to multiple lines of treatment have limited therapeutic possibilities. Asciminib is a first‐in‐class tyrosine kinase inhibitor (TKI) that inhibits the ABL Myristoyl Pocket (STAMP or Specifically Targeting the ABL Myristoyl Pocket) within the BCR::ABL1 oncoprotein. This retrospective Italian analysis reports the efficacy and safety outcomes of asciminib in treating 77 CML patients in chronic phase (CML‐CP) within a compassionate use setting. Patients were heavily pretreated with a median of 3 TKIs (55.8% had prior ponatinib exposure). Overall, 57.1% and 42.9% patients switched to asciminib because of resistance and intolerance, respectively. Asciminib maintained or improved molecular responses (MRs) in most patients: as best response, 41 patients (53%) achieved a MR3 or better, with 25 patients (32.5%) reaching deep molecular response (DMR). Greater percentages of intolerant patients achieved MR compared with resistant patients, although the probability of reaching at least a MR3 was not significant between the two groups ( p = 0.116). Patients with the T315I mutation responded to asciminib, while ponatinib pre‐treated patients showed lower MR improvements compared to naïve patients and had a lower probability to reach a MR3 versus naïve patients ( p = 0.0262). These results highlight asciminib remarkable tolerability and efficacy in real‐world CML‐CP patient population, including heavily pretreated patients, those intolerant and resistant to previous TKIs, and presenting several comorbidities. Trail Registration The identification code for the MAP is CABL001AIT01M.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmPyrazolesProtein Kinase InhibitorsLeukemia, Myeloid, Chronic-PhaseHumansMaleFemaleMiddle AgedAgedCompassionate Use TrialsAdultRetrospective StudiesItalyAged, 80 and overYoung AdultLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablTreatment OutcomeNiacinamide

Stichwörter der Autor:innen

TKI resistance/intoleranceasciminibchronic myeloid leukemia in chronic phase (CML‐CP)major molecular response (MMR)real‐worldtyrosine kinase inhibitor (TKI)

Substanzen

asciminibPyrazolesProtein Kinase InhibitorsFusion Proteins, bcr-ablNiacinamide

Autor:innen und Institutionen

  • Division of Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy.
  • Hematology and Transplantation Unit, University of Bari, Bari, Italy.
  • Division of Haematology, A.O.U. Città della Salute e della Scienza, Turin, Italy.
  • Division of Hematology, Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria, Italy.
  • Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  • Hematology Unit, Cardarelli Hospital, Napoli, Italy.

ORCID-Profile: Massimo Breccia, Felicetto Ferrara, Alessandra Iurlo, Luigia Luciano, Marco Santoro, Federica Sorà

Förderung

  • Novartis Farma Italy

Zitieren

APA

Breccia, M., Rossi, A. R., Giai, V., Martino, B., Fava, C., Annunziata, M., Abruzzese, E., Binotto, G., Baratè, C., Nardozza, A. P., Misto, A., Coco, P., Calafiore, V., Carraro, M. C., Cattina, F., Cavazzini, F., Corsetti, M. T., Crucitti, L., Crugnola, M., …, & Castagnetti, F. (2025). Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population. Hematological Oncology. https://doi.org/10.1002/hon.70101

Vancouver

Breccia M, Rossi AR, Giai V, Martino B, Fava C, Annunziata M, et al. Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population. Hematological Oncology. 2025. doi:10.1002/hon.70101

BibTeX
@article{Breccia2025,
  author = {Breccia, Massimo and Rossi, Antonella Russo and Giai, Valentina and Martino, Bruno and Fava, Carmen and Annunziata, Mario and Abruzzese, Elisabetta and Binotto, Gianni and Baratè, Claudia and Nardozza, Aurelio Pio and Misto, Alessandra and Coco, Paola and Calafiore, Valeria and Carraro, Maria Cristina and Cattina, Federica and Cavazzini, Francesco and Corsetti, Maria Teresa and Crucitti, Lara and Crugnola, Monica and Di Veroli, Ambra and Ditonno, Paolo and Ermacora, Anna and Ferrara, Felicetto and Genua, Angelo and Gozzini, Antonella and Impera, Stefana and Iurlo, Alessandra and Levato, Luciano and Luciano, Luigia and Miggiano, Maria Cristina and De Gobbi, Marco and Santoro, Marco and Scappini, Barbara and Scortechini, Anna Rita and Patriarca, Andrea and Rosati, Serena and Russo, Sabina and Sancetta, Rosaria and Sanpaolo, Grazia and Santeramo, Teresa Maria and Sibilla, Silvia and Sorà, Federica and Sportoletti, Paolo and Stagno, Fabio and Trabacchi, Elena and Castagnetti, Fausto},
  title = {Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70101}
}
Kostenlos starten →